Sign In
Buy CRVS
$11.60
-0.0900 (-0.770%)
At Close: Jun 03, 2026
H.C. Wainwright Maintains a Buy Rating on Tyme Technologies (TYME) - Markets
11:08am, Sunday, 28'th Jun 2020
In a report issued on June 24, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Tyme Technologies (TYME
Zacks: Analysts Anticipate Corvus Pharmaceuticals Inc (NASDAQ:CRVS) Will Announce Earnings of -$0.30 Per Share
06:54am, Thursday, 25'th Jun 2020
Brokerages expect Corvus Pharmaceuticals Inc (NASDAQ:CRVS) to report ($0.30) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provide
Codexis (CDXS) Gets a Buy Rating from H.C. Wainwright - Markets
10:21am, Wednesday, 24'th Jun 2020
H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Codexis (CDXS – Research Report) today and set a price
Neoleukin Therapeutics (NLTX) Receives a Buy from Mizuho Securities - Markets
02:17am, Wednesday, 24'th Jun 2020
Mizuho Securities analyst Mara Goldstein reiterated a Buy rating on Neoleukin Therapeutics (NLTX – Research Report) yesterday and set a
Under-the-Radar Reasons Mining Industry Could Experience a “Golden Year” - NetworkNewsWire
01:00pm, Tuesday, 23'rd Jun 2020
NetworkNewsWire Editorial Coverage: Whoever has the gold, makes the rules—this expression seems apt for 2020, as a confluence of factors has analysts predicting a “golden year” for the mining in
H.C. Wainwright Reiterates Their Buy Rating on Zomedica Pharmaceuticals (ZOM) - Markets
02:36pm, Wednesday, 17'th Jun 2020
In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Zomedica Pharmaceuticals (ZOM – Research
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on KalVista Pharmaceuticals
Analysts Are Bullish on These Healthcare Stocks: Kindred Biosciences (KIN), Gilead Sciences (GILD) - Markets
10:13am, Wednesday, 10'th Jun 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Kindred Biosciences
Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel b
The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant
12:00am, Friday, 29'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 28)
ADC Therapeutics SA (NYSE:...
Corvus Pharmaceuticals to Present at the Jefferies 2020 Virtual Healthcare Conference
12:00pm, Wednesday, 27'th May 2020
BURLINGAME, Calif., May 27, 2020 -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of.
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
12:00am, Sunday, 24'th May 2020
Biotech stocks closed the week ended May 22 higher, with stray clinical readouts and COVID-19 drug- and vaccine-related news moving stocks in the sector.
Surface Oncology Inc (...
What Makes Corvus (CRVS) a New Buy Stock
04:00pm, Wednesday, 20'th May 2020
Corvus (CRVS) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
More Data, More Digitalization Creates More Cyber Risks
12:00am, Friday, 15'th May 2020
Corvus Insurance Holdings offers cyber risk insurance that relies on advanced technology to underwrite coverage for companies with up to $2 billion in annual revenues.
BURLINGAME, Calif., May 13, 2020 -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of.
